AB0111 CHARACTERIZING THE PRE-DISEASE STATE OF PSORIATIC ARTHRITIS: CXCL10 LEVELS ARE ASSOCIATED WITH SUBCLINICAL SYNOVITIS IN PATIENTS WITH PSORIASIS
Authors: V. Pulito-Cueto, S. Armesto, S. Remuzgo-Martínez, R. López-Mejías, M. Sebastián Mora-Gil, J. G. Ocejo-Vinyals, A. Corrales, V. Calvo-Río, A. M. Salas Martínez, M. González López, C. López-Obregón, E. Aurrecoechea, L. Rodriguez Rodriguez, C. Aguirre Portilla, M. A. González-Gay, R. Blanco, F. Genre Romero, J. Rueda-Gotor
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> The chemokine C-X-C Motif Chemokine Ligand 10 (CXCL10) has been found to be elevated in those patients with psoriasis (PsO) who will develop psoriatic arthritis (PsA), thus being proposed as a predictor of joint involvement [1]. CXC10 progressively declines in these PsO patients until the diagnosis of PsA and further, in parallel with the duration of the disease [2]. In contrast, CXCL10 remains invariable on time in the rest of PsO patients. Subclinical ultrasound synovitis may be considered a pre-disease state of PsA [3]. CXCL10 serum levels in patients with preclinical PsA are still unknown. <h3>Objectives</h3> To better characterize the preclinical phase of PsA and to assess the relationship of CXCL10 levels with subclinical joint involvement in PsO patients. <h3>Methods</h3> 62 patients with PsO without PsA were included, all of them naïve to biological therapy. Ultrasonography (US) was performed on the wrist and metacarpophalangeal 1–5 joints (MCP), proximal interphalangeal 1–5 joints (PIP), and distal interphalangeal 2–5 joints (DIP) bilaterally, and grey scale (GS) synovitis were scored semiquantitatively (0–3) using the OMERACT scoring system. Serum CXCL10 levels were also determined by ELISA in all the patients. <h3>Results</h3> 31 men and 31 women were recruited. GS synovitis ≥1 was present in 30 patients, 10 men and 20 women, while only 7 patients exhibited GS synovitis ≥2, 4 men and 3 women. The mean logCXCL10 was inferior in patients showing any grade of GS, both in the whole group and after stratifying by sex (Table 1), although the difference was only statistically significant for grade 1 of GS in men (p=0.02) and grade 2 of GS in women (p=0.02). <h3>Conclusion</h3> PsO patients with subclinical synovitis show lower serum levels of CXCL-10 than patients without it, as occurs in patients with established PsA. This finding confirms a close relationship between this biomarker and joint involvement in PsO and supports its potential use as a predictor marker in the preclinical phase of PsA. <h3>Reference</h3> [1]Arthritis Rheumatol. 2016 Dec;68(12):2911-2916. [2] Br J Dermatol. 2020 Nov;183(5):920-927. [3] Nat Rev Rheumatol. 2021 Apr;17(4):238-243. <h3>Acknowledgements</h3> This study was funded by Instituto de Salud Carlos III (ISCIII) through the project PI20/00059, co-funded by European Regional Development Fund (ERDF), and by NVAL19/22 (IDIVAL) awarded to JR-G. VP-C is supported by PI18/00042 (ISCIII), co-funded by ERDF. RL-M is recipient of the grant CPII21/00004 (ISCIII), co-funded by the European Social Fund. MSM-G is supported by TRANSVAL22/01 (IDIVAL). JR-G is beneficiary of a program of intensification funded by 'Fundación Española de Reumatología (FER)´. <h3>Disclosure of Interests</h3> Verónica Pulito-Cueto: None declared, Susana Armesto: None declared, Sara Remuzgo-Martínez: None declared, Raquel López-Mejías: None declared, María Sebastián Mora-Gil: None declared, J. Gonzalo Ocejo-Vinyals: None declared, Alfonso Corrales: None declared, Vanesa Calvo-Río: None declared, Ana María Salas Martínez: None declared, Marcos González López: None declared, Cristina López-Obregón: None declared, Elena Aurrecoechea: None declared, Luis Rodriguez Rodriguez: None declared, Carolina Aguirre Portilla: None declared, Miguel A González-Gay Speakers bureau: Abbvie, Pfizer, Roche, Sanofi, Lilly, Celgene, MSD and GSK, Grant/research support from: Abbvie, MSD, Jansen and Roche, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD and Roche, Fernanda Genre Romero: None declared, Javier Rueda-Gotor: None declared.